We are seeking submissions from interested stakeholders on the Guideline. This consultation web portal is open from October 20^th to November 19^th 2023.  Requests for time extensions cannot be granted. Please provide concise responses. Comments will be considered and addressed by the multidisciplinary guideline development group.  Deidentified comments will be made available to the Australian National Health and Medical Research Council and publicly available on the final Guideline web pages.

We have adapted the evidence-based, Unexplained Infertility guideline, developed by the European Society of Human Reproduction and Embryology (ESHRE), to our Australian setting, using an internationally accepted and rigorous ADAPTE process for guidelines.

Please refer to the ESHRE guideline for information about the guideline, including scope, target users, patient population and outcomes. Notably, two leaders in the UI field in Australia were engaged throughout the ESHRE process alongside evidence and guideline development experts from CRE WHiRL. There was Australian engagement in scope, clinical questions, recommendation development and extensive consultation in the EHSRE public consultation process.

The ESHRE Guideline was then adapted, led by the NHMRC Centre for Research Excellence in Reproductive Life (CRE WHiRL). Methods and details are provided in the Guideline and associated documents. Governance included a steering committee, reference group, guideline development group and integrity group. The Australian guideline development group is comprised of 12 multidisciplinary health professionals, researchers and consumer representatives, all experts in the topic area of infertility. All were trained in guideline and evidence synthesis best practice.  Evidence synthesis was completed by an ESHRE expert team and guideline development followed world’s best practice, with recommendations reflecting an integration of evidence, health professional expertise and consumer perspectives. This evidence was used to inform recommendations which were only altered to align with NHMRC methods, or considering nuances in the Australian settings (e.g. health care system, geographical and population factors such as Indigenous populations). Adaptations to the ESHRE recommendations were drafted at face to face meetings, online meetings and by email.  Methods are detailed in the guideline document. A comprehensive translation program will follow, along with evaluation of impact.

Please consider the extensive and robust process to date and provide evidence for all feedback that challenges the content of the recommendations. Opinions and review articles are not considered to be evidence.

All insights into nuances in the Australian setting are welcome and do not require evidence to be provided.

Evidence was included only if it met rigorous pre-specified requirements. Whilst additional evidence cannot be included in the systematic reviews, additional evidence can be included in the narrative review sections where it:

• will influence a recommendation or practice point
• meets rigorous inclusion criteria that align with a PICO, is a high-quality systematic review, meta-analysis, randomised controlled trial, cohort, or observational study as outlined in the technical report